SCHEMBL4286426

SCHEMBL4286426

CCOC(=O)c1ccc(N(C)C(C)=O)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 2/20 0.58
CA1 P00915 2/20 0.58
CA2 P00918 2/20 0.58
CA7 P43166 2/20 0.58
CA9 Q16790 2/20 0.58
CA14 Q9ULX7 2/20 0.58
ESR1 P03372 1/20 0.58
ESR2 Q92731 1/20 0.58
LMNA P02545 3/20 0.56
CYP1A2 P05177 1/20 0.56
CYP3A4 P08684 1/20 0.56
MAOA P21397 1/20 0.56
RAB9A P51151 5/20 0.54
NPC1 O15118 4/20 0.54
MAPT P10636 4/20 0.54
ALDH1A1 P00352 4/20 0.54
L3MBTL1 Q9Y468 1/20 0.54
HPGD P15428 4/20 0.50
HTT P42858 2/20 0.50
SMN1; SMN2 Q16637 3/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23084173 0.91 MAPT (0.65) CA12CA1CA2CA7CA9
SCHEMBL14311840 0.86 CA12 (0.58) CA12CA1CA2CA7CA9
SCHEMBL14175173 0.86 CA12 (0.58) CA12CA1CA2CA7CA9
SCHEMBL13934090 0.84 CA1 (0.59) CA12CA1CA2CA7CA9
SCHEMBL31322476 0.84 CA1 (0.51) CA12CA1CA2CA7CA9
SCHEMBL5190217 0.84 ALDH1A1 (0.70) CA12CA1CA2CA7CA9
SCHEMBL15425 0.84 ALDH1A1 (0.70) CA12CA1CA2CA7CA9
SCHEMBL7794161 0.83 CA1 (0.58) CA12CA1CA2CA7CA9
Acetic Acid SCHEMBL26103642 0.83 ALDH1A1 (0.65) CA12CA1CA2CA7CA9
SCHEMBL20749751 0.82 CA1 (0.61) CA12CA1CA2CA7CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090247593-A1 N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES H. LUNDBECK A/S (DK) 2009-10-01 US disclosed
EP-1803455-A1 N-thiazol-2-yl-benzamide derivatives H.Lundbeck A/S (DK) 2007-07-04 EP disclosed
EP-1682129-B1 N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES LUNDBECK & CO AS H (DK) 2007-02-21 EP disclosed
EP-1682129-A1 N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES H. LUNDBECK A/S (DK) 2006-07-26 EP disclosed
US-20060154974-A1 N-thiazol-2-yl-benzamide derivatives H. LUNDBECK A/S (DK) 2006-07-13 US disclosed
WO-2005039572-A1 N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES H. LUNDBECK A/S (DK) 2005-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090247593-A1 N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES ADORA2A, ADORA3, ADORA1 CA12 4659/4885CA1 3728/4885CA2 3386/4885
US-20060154974-A1 N-thiazol-2-yl-benzamide derivatives ADORA2A, ADORA3, ADORA1 CA12 4659/4885CA1 3728/4885CA2 3386/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.